The rational drug design approach to drug discovery has increased considerably in the last decade. It is dependent on a multidisciplinary team that works as an integrated unit. Recent years have seen an increase in the complexity of drug discovery research and a constant rise in new technologies and methods used by a drug discovery team. Consequently, medicinal chemists have been forced to increase their knowledge base extensively and currently face a steep learning curve. The "Molecular Conceptor Learning Series" is an innovative, computer-based learning solution that aims to bring together, in a ready-digested format, knowledge of medicinal chemistry, drug design, cheminformatics, structural bioinformatics and molecular modeling, necessary to the skills, techniques and approaches used by a drug discovery team as a whole. It provides all the information needed by the medicinal chemist to allow him to analyze, understand and make informed decisions concerning the design of a drug, thus enabling them to contribute effectively to the drug discovery process. Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Drug Design and Research is an interdisciplinary, open access, peer reviewed journal that brings about most recent research in all related fields of Drug Design and Research focusing upon the successes in drug designing methodologies and new drugs that have been created and the experiences and developments from the joined utilization of chemical and biological research.
Drug Design and Research is a widespread that covers following topics not constrained to the following areas:
♦ Bioanalytics Techniques
♦ Bioavailability & Bioequivalence
♦ Drug Extraction Studies
♦ Thermal Analysis
♦ Tracer Techniques
♦ Drug Analytics
♦ Analysis of drugs in Biological fluids
♦ Pharmaceutical Analysis
♦ Clinical and Medicinal Chemistry
♦ Drug Chemistry
♦ Drug Biochemistry
♦ Immunology & Clinical Toxicology
♦ Analog Based Drug Design
The future of drug design and the patenting of new therapeutics will rely on our ability to unravel the complexities of the epigenome in normal and disease states. Proper epigenetic regulation is essential for normal differentiation in embryogenesis and development. Conversely, abnormal epigenetic regulation is a feature of complex diseases, including cancer, diabetes, heart disease and other pathologies. Epigenetic therapies hold promise for a wide range of biological applications, from cancer treatment to the establishment of induced pluripotent stem cells. The creation of more specific and effective epigenetic therapies, however, requires a more complete understanding of epigenomic landscapes.
We provide Drug Design & Patenting course in two levels as Professional Designation for undergraduate students and Advance PG Program for Graduated Students. The details of the courses are as below:
The above program curriculum will help students to ensure that the following job opportunities are waiting for them. We can conclude that requirement of drug designers are the necessity for several pharmaceutical related research laboratories and industry. Research and lab work must be done before new drugs and medicines can be produced for widespread use. The pharmaceutical industry spends more money on the research and development stages than most other industries. It usually takes the work of a team of scientists to work on the development and design of new drugs.Microbiologists, physiologists, medical scientists, organic chemists and botanists are just a few of the different types of scientists who work in the pharmaceutical industry. Drug designers usually work in an office or a laboratory setting. Communication skills are useful if you wish to work in drug design because you frequently work with a team of other scientists to develop and test the new drugs.